Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

163.10 +1.92 (+1.19%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

41 42 Next >

Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects ↗

January 19, 2023

Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem.

Via Benzinga

Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide ↗

January 19, 2023

Cantor Fitzgerald published around 40-page deep dive ahead of Novo Nordisk A/S's (NYSE: NVO) SELECT CV outcomes study, which is guided to complete in ~mid-2023.

Via Benzinga

Novartis CEO Refutes Recent Report Of Weighing Options For Ophthalmology, Respiratory Units ↗

January 10, 2023

Novartis AG (NYSE: NVS) said it would narrow its focus on five core therapeutic areas, including cardiovascular, immunology, neurodegenerative diseases, solid tumors, and hematology.

Via Benzinga

3 Biotech Companies to Watch in 2023 ↗

January 06, 2023

These biotech companies to watch are remarkably strong businesses that offer healthy upside potential as we head into a new year.

Via InvestorPlace

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗

January 06, 2023

Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.

Via Investor's Business Daily

Hopeful Golden Cross Forms On Novartis's Chart ↗

December 26, 2022

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

December 26, 2022

Via Benzinga

2 Top Biotech Stocks to Buy Right Now ↗

January 06, 2023

These two pharmaceutical companies pay market-beating dividends to shareholders.

Via The Motley Fool

GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca ↗

December 30, 2022

GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding war.'

Via Benzinga

2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond ↗

December 29, 2022

These two biotechs are flying high right now.

Via The Motley Fool

Elon Musk Tells Employees Tesla Will Be 'Most Valuable Company On Earth, Sam Bankman-Fried Set To Enter Plea On Fraud Case, Twitter 'Should Feel Faster': Today's Top Stories ↗

December 29, 2022

Reuters

Via Benzinga

A Bullish Sign Appears On Novartis's Chart ↗

December 23, 2022

Via Benzinga

Novartis' Rare Blood Disorder Therapy Aces Second Late-Stage Trial ↗

December 08, 2022

Via Benzinga

Novartis Settles Antitrust Cases Related To Generic Entry For Hypertension Drug ↗

December 29, 2022

Novartis AG (NYSE: NVS) will pay $245 million to end antitrust litigation accusing the company of trying to delay the U.S. launch of generic versions of its Exforge, which treats hypertension to lower...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

December 23, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

3 Ridiculously Cheap Dividend Stocks That Yield More Than 3% ↗

December 22, 2022

You're getting a lot of bang for your buck with these stocks.

Via The Motley Fool

Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says ↗

December 20, 2022

Via Benzinga

Pfizer, Novartis Are Among Overbought Healthcare Stocks: Are They Worth A Look? ↗

December 14, 2022

The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies. Here’s the latest list of major overbought players in this sector, with an RSI...

Via Benzinga

A Career Politician Who Regularly Trades The SPY, Picked Up There 3 High Yielding ETFs Instead ↗

December 13, 2022

Representative Robert Wittman (R-VA) is the vice-ranking member of the House Armed Services Committee and also serves on the Committee on Natural Resources.

Via Benzinga

Novartis Shares Detailed Results From Experimental Drug For Rare Blood Disorder ↗

December 13, 2022

Via Benzinga

Why Merck's $250 Million Investment In Moderna May Have Just Paid Off ↗

December 13, 2022

Merck opted into Moderna's cancer vaccine. Now, the companies have Phase 2 data.

Via Investor's Business Daily

CLVS Stock Alert: What to Know as Clovis Oncology Files for Bankruptcy ↗

December 12, 2022

Clovis Oncology (CLVS) stock is on the move Monday as investors react to the pharmaceutical company filing for bankruptcy protection.

Via InvestorPlace

Erasca Oulicenses Its Mid-Stage Cancer Program To Novartis, Raises $100M Via Equity Offering ↗

December 09, 2022

Via Benzinga

3 Hot Stocks That Could Live Up to Their Lofty Valuations ↗

December 08, 2022

These companies have long runways of growth ahead

Via The Motley Fool

MorphoSys Inks Licensing Agreement With Novartis For Preclinical Cancer Programs ↗

December 07, 2022

Via Benzinga

Novartis' Kisqali Prolongs Progression Free Survival Benefit In Metastatic Breast Cancer Versus Chemo ↗

December 07, 2022

Via Benzinga

First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM

December 02, 2022

By Rachael Green, Benzinga

Via News Direct

Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors ↗

December 02, 2022

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

November 28, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

3 Biotech Stocks Smart Investors Should Be Buying Up Now ↗

November 24, 2022

These three biotech stocks could be among the best ways to play this uncertain market for those looking for long-term growth.

Via InvestorPlace

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

Headline News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today